Welcome to our dedicated page for Revance Therapeutics news (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeutics stock.
Revance Therapeutics, Inc. (symbol: RVNC) is a specialty biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative botulinum toxin products for various aesthetic and therapeutic uses. Leveraging its proprietary portfolio of botulinum toxin compounds and the patented TransMTS® peptide delivery system, Revance aims to address unmet needs in the $3 billion neurotoxin market.
The company’s unique TransMTS technology allows for the delivery of botulinum toxin A in two distinctive formulations: a needle-free topical form and an injectable form that targets the site of injection for a potentially longer-lasting effect. Revance is actively pursuing clinical development for two main product candidates: Topical RT001 and Injectable RT002. RT001 is a topical gel with the potential to become the first commercially available non-injectable botulinum toxin dose form.
Additionally, Revance has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Their primary products, DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics, are central to their aesthetic and therapeutic offerings.
Revance operates through two main business segments: Product and Service. The Products segment, which generates the majority of the company’s revenue, focuses on the research and development of aesthetic and therapeutic products. Recent achievements and ongoing developments reflect the company’s commitment to advancing the field of neuromodulation.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced the grant of 41,900 inducement restricted stock awards (RSAs) to 15 new employees. These RSAs vest over four years, with 25% vesting on each anniversary of the vesting commencement date. The grants were approved by the Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4). Revance specializes in innovative aesthetic and therapeutic products, including its neuromodulator, DaxibotulinumtoxinA for Injection, currently pursuing U.S. regulatory approval after completing Phase 3 trials.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced positive topline efficacy and safety results from its Phase 2 study of DaxibotulinumtoxinA for Injection, targeting upper facial lines including glabellar, forehead, and lateral canthal lines. The study involved 48 subjects over 36 weeks. Key results showed a 95.8% success rate for both glabellar and forehead lines at Week 4, with median effect durations between 24-35 weeks. Safety results highlighted no serious adverse events, with 100% patient satisfaction reported. The study enhances understanding of DaxibotulinumtoxinA's application in aesthetic treatments.
Revance Therapeutics (NASDAQ: RVNC) will relocate its headquarters from Newark, California, to Nashville, Tennessee, investing over $10 million and creating approximately 150 jobs over the next five years. The new headquarters will feature a training and education center for employees and healthcare providers. Revance is known for its innovative aesthetic and therapeutic products, including the investigational neuromodulator DaxibotulinumtoxinA for Injection, currently under FDA review. This move marks a significant expansion for the company, promising growth and innovation in Nashville.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced the FDA has deferred a decision on its Biologics License Application for DaxibotulinumtoxinA for Injection, intended for treating moderate to severe glabellar lines. This delay, communicated on November 24, 2020, is due to the need for an inspection of Revance's Northern California facility, which was hindered by COVID-19 travel restrictions. The FDA stated there are no additional review issues, and Revance is prepared for the inspection as soon as conditions allow. The company remains optimistic about its financial position and the potential approval timeline.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced that CEO Mark Foley will participate in a fireside chat during the Piper Sandler 32nd Annual Virtual Healthcare Conference, available online starting December 1, 2020. The conference runs from December 1-3, 2020. Revance specializes in innovative aesthetic and therapeutic products, including DaxibotulinumtoxinA for Injection, which targets facial wrinkles and spasticity disorders. The company aims for U.S. regulatory approval in 2020 and has a portfolio of services, including the RHA® Collection of dermal fillers.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced the grant of 40,500 inducement restricted stock awards (RSAs) to nine employees, approved by its Compensation Committee. The RSAs will vest over four years, with 25% vesting each year, contingent upon continued employment. This move aligns with NASDAQ Listing Rule 5635(c)(4) for new hires. Revance focuses on innovative aesthetic and therapeutic products, highlighted by its investigational neuromodulator, DaxibotulinumtoxinA for Injection, currently seeking U.S. regulatory approval.
Revance Therapeutics (Nasdaq: RVNC) announced its participation in the Stifel 2020 Virtual Healthcare Conference from November 16-18. CEO Mark Foley will host a virtual fireside chat on November 17 at 11:00 a.m. PT / 2:00 p.m. ET. The conference can be accessed via the Investor Relations section of Revance's website, with a replay available for 30 days post-event.
Revance focuses on innovative aesthetic and therapeutic solutions, including its next-generation neuromodulator, DaxibotulinumtoxinA for Injection, which has completed Phase 3 trials targeting glabellar lines and is seeking U.S. regulatory approval.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced disappointing results from its Phase 2 trial of DaxibotulinumtoxinA for Injection, aimed at treating plantar fasciitis. The study, involving 155 patients, showed that while both doses provided some pain relief, neither met the primary efficacy endpoint compared to placebo. Notably, DaxibotulinumtoxinA was well-tolerated with no serious adverse events. CEO Mark Foley emphasized shifting focus to established neuromodulator indications despite these results. Upcoming topline data from the JUNIPER Phase 2 trial for upper limb spasticity is anticipated in Q1 2021.
Revance Therapeutics (Nasdaq: RVNC) reported Q3 2020 financial results with revenues of $3.8 million, a substantial increase from $46,000 in Q3 2019. The company launched its RHA® Collection of dermal fillers, generating $3 million in initial revenues. However, FDA inspection delays for its BLA submission could impact approval timelines for DaxibotulinumtoxinA. The company reported net losses of $81.3 million for Q3, up from $41.4 million in 2019. Revance anticipates 2020 operating expenses between $285 to $295 million and has sufficient cash to fund operations into 2023.
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company, announced its participation in the Credit Suisse 29th Annual Healthcare Conference, scheduled for November 9-12. Chief Financial Officer Toby Schilke will present on November 10 at 7:15 a.m. PT / 10:15 a.m. ET. The live audio webcast will be available on the company's website, with a replay accessible for 30 days post-event. Revance focuses on innovative aesthetic and therapeutic offerings, particularly its investigational neuromodulator, DaxibotulinumtoxinA for Injection, aimed at treating facial lines and various therapeutic indications.
FAQ
What is the current stock price of Revance Therapeutics (RVNC)?
What is the market cap of Revance Therapeutics (RVNC)?
What does Revance Therapeutics, Inc. specialize in?
What is the TransMTS® peptide delivery system?
What are the main products of Revance Therapeutics?
What is RT001?
What are the business segments of Revance Therapeutics?
How does Revance's TransMTS technology benefit its products?
What is the significance of DaxibotulinumtoxinA?
What is the RHA Collection?
What is the HintMD platform?
How does Revance's Product segment contribute to its revenue?
